Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 13/20 | 0.55 |
| ▸ | P2RX2 | Q9UBL9 | 13/20 | 0.55 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CDK4 | P11802 | 2/20 | 0.40 |
| ▸ | CCND1 | P24385 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | BCL6 | P41182 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2250237 | 1.00 | P2RX3 (0.55) | P2RX3P2RX2CDK7CDK9CDK1 | |
| SCHEMBL30215837 | 0.95 | P2RX3 (0.53) | P2RX3P2RX2BCL6 | |
| SCHEMBL2248211 | 0.95 | P2RX3 (0.53) | P2RX3P2RX2BCL6 | |
| SCHEMBL18084458 | 0.93 | P2RX3 (0.61) | P2RX3P2RX2 | |
| SCHEMBL5530415 | 0.92 | P2RX3 (0.66) | P2RX3P2RX2CDK1CDK4CCND1 | |
| SCHEMBL5523690 | 0.88 | P2RX3 (0.64) | P2RX3P2RX2 | |
| SCHEMBL2254702 | 0.87 | P2RX3 (0.62) | P2RX3P2RX2 | |
| SCHEMBL30215850 | 0.87 | P2RX3 (0.62) | P2RX3P2RX2 | |
| SCHEMBL30215846 | 0.85 | P2RX3 (0.60) | P2RX3P2RX2BCL6 | |
| SCHEMBL2248976 | 0.85 | P2RX3 (0.60) | P2RX3P2RX2BCL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066309-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250025462-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC (US) | 2025-01-23 | — | — | US | disclosed |
| US-20230100975-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066309-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | P2RX3 1/4885P2RX2 3/4885CDK7 1380/4885 |
| US-20230100975-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | P2RX3 1/4885P2RX2 3/4885CDK7 1380/4885 |
| US-20250025462-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885P2RX2 2/4885CDK7 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.